The potential of multilamellar vesicles (MLVs) as carriers of cis-bis-cyclopentenecarboxylato-1,2-diaminocyclohexane
platinum(II) (
CPDP), a lipophilic
cisplatin derivative, was assessed. MLVs composed of dimyristoyl
phosphatidylcholine (
DMPC),
dimyristoyl phosphatidylglycerol (
DMPG), and
cholesterol at different molar ratios were tested. The MLV-
CPDP preparation with the highest antitumor activity against
L1210 leukemia in vivo was
DMPC:
DMPG 7:3-
CPDP. The encapsulation efficiency of this preparation was 66 +/- 4% (SD); the stability in
0.9% NaCl solution at 4 degrees C was 89% at 14 days and 93% 18 h after incubation in human AB serum at 37 degrees C. The toxicities of
DMPC:
DMPG 7:3-
CPDP and free
CPDP (suspended in
hydroxypropyl cellulose) administered i.p. were similar (50% lethal dose = 75 versus 91 mg/kg; blood
urea nitrogen values 96 h after the administration of the 50% lethal dose = 32.0 versus 34.4 mg/dl). The mean %T/C [(median survival time of treated mice divided by median survival time of control mice) X 100] obtained after a single i.p. injection of the optimal dose of each preparation tested was 215 (range 200 to 232) for
DMPC:
DMPG 7:3-
CPDP, 175 (range 158 to 209) for
DMPG-
CPDP, 162 (range 136 to 179) for free
CPDP, and 178 (range 169 to 189) for
cisplatin. Using a multiple i.p. injection schedule (
injections on Days 1, 5, and 9),
DMPC:
DMPG 7:3-
CPDP was more active than free
CPDP and
cisplatin (%T/C: 403, 284, and 253% respectively).
DMPC:
DMPG 7:3-
CPDP is less toxic and more active against
L1210 leukemia in vivo than is
cisplatin. The encapsulation of
CPDP in MLVs composed of
DMPC:
DMPG 7:3 provides an adequate vehicle for the administration of this lipophilic compound and enhances its antitumor activity against
L1210 leukemia.